Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

2.

Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.

Chen F, Feng Y, Zheng K, De Keyzer F, Li J, Feng Y, Cona MM, Wang H, Jiang Y, Yu J, Marchal G, Verfaillie C, De Geest B, Oyen R, Ni Y.

PLoS One. 2012;7(7):e41140. doi: 10.1371/journal.pone.0041140. Epub 2012 Jul 18.

3.

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.

Cancer Res. 2002 May 15;62(10):2731-5.

4.

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.

Clin Cancer Res. 2009 Aug 1;15(15):4954-62. doi: 10.1158/1078-0432.CCR-08-3317. Epub 2009 Jul 21.

5.

Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour.

Borkamo ED, Fluge O, Mella O, Akslen LA, Bruland O, Dahl O.

Radiother Oncol. 2008 Mar;86(3):435-42. doi: 10.1016/j.radonc.2008.01.022. Epub 2008 Mar 4.

PMID:
18313158
6.

Effect of early and delayed difluoromethylornithine pretreatment upon cyclophosphamide chemotherapy.

Johnson M, Shaw M, Rubenstein M, Guinan P.

Clin Physiol Biochem. 1990;8(1):11-5.

PMID:
2108838
7.

In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.

Cyran CC, Schwarz B, Paprottka PM, Sourbron S, von Einem JC, Dietrich O, Hinkel R, Clevert DA, Bruns CJ, Reiser MF, Nikolaou K, Wintersperger BJ.

Cancer Imaging. 2013 Dec 16;13(4):557-66. doi: 10.1102/1470-7330.2013.0049.

8.

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A.

Ann Oncol. 2006 Feb;17(2):232-8. Epub 2005 Dec 1.

PMID:
16322118
9.

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A.

Lab Invest. 2012 Jul;92(7):952-66. doi: 10.1038/labinvest.2012.65. Epub 2012 Apr 30.

11.

Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.

Mainetti LE, Rico MJ, Fernández-Zenobi MV, Perroud HA, Roggero EA, Rozados VR, Scharovsky OG.

Ann Oncol. 2013 Sep;24(9):2310-6. doi: 10.1093/annonc/mdt164. Epub 2013 May 10.

PMID:
23666914
12.

The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.

Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K.

Cancer Chemother Pharmacol. 2006 Sep;58(3):354-60. Epub 2005 Dec 7.

PMID:
16333676
13.

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS.

Cancer Res. 2006 Feb 1;66(3):1664-74.

14.

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.

Gebbia V, Serretta V, Borsellino N, Valerio MR; GSTU Foundation.

Urology. 2011 Nov;78(5):1125-30. doi: 10.1016/j.urology.2011.08.010.

PMID:
22054386
15.

Tumor oxygen dynamics: correlation of in vivo MRI with histological findings.

Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP.

Neoplasia. 2003 Jul-Aug;5(4):308-18. doi: 10.1016/S1476-5586(03)80024-6.

17.

Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.

Di Lorenzo G, Autorino R, De Laurentiis M, Forestieri V, Romano C, Prudente A, Giugliano F, Imbimbo C, Mirone V, De Placido S.

Cancer Biol Ther. 2007 Mar;6(3):313-7. Epub 2007 Mar 6.

PMID:
17327701
18.

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.

Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS.

Cancer Res. 2005 Aug 15;65(16):7045-51.

19.

Combined treatment of Dunning R3327 rat prostatic tumor with the 5alpha-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide.

Zaccheo T, Giudici D, Panzeri A, di Salle E.

Cancer Chemother Pharmacol. 2000;45(1):31-7.

PMID:
10647498
20.

Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.

El-Arab LR, Swellam M, El Mahdy MM.

J Egypt Natl Canc Inst. 2012 Mar;24(1):15-22. doi: 10.1016/j.jnci.2011.12.002. Epub 2012 Jan 17.

Supplemental Content

Support Center